• TS-GS is FDA cleared for the long-term improvement in the appearance of cellulite on the buttocks and thighs, with no loss of benefit for up to 3 years (Tables 1 and 2 ) 1-3 • The purpose of this observational study was to collect data on TS-GS treatment administration, safety, and effectiveness in real-life clinical practice • Cellulite refers to the dimpled appearance of skin which is estimated to affect approximately 95% of post-pubertal women of all races • The appearance of cellulite has been associated with significant social stigma and can adversely affect self-esteem • Tissue stabilized-guided subcision (TS-GS; Cellfina(R) System, Ulthera, Inc.) builds on the proven approach of dermal undermining, or subcision; the system is designed to provide vacuum-assisted control of both the depth and area of tissue release to allow for precise, reproducible and consistently effective treatment results ( Figure 1) 1 BACKGROUND AND OBJECTIVE
• Prospective, multi-center, non-randomized, standard of care, observational registry study • 53 female subjects were enrolled at 8 sites and treated using a TS-GS device by investigator or sub-investigator according to the sites' standard of care Registry Endpoints and Analyses • Primary:
-Subject-assessed Global Aesthetic Improvement Score (GAIS) at day 180.
• Secondary:
-Physician Global Aesthetic Improvement Score (GAIS) at Day 180 post-treatment -Quality of life questionnaire at the treatment visit, 30, 90, and 180 day follow-up visits to determine effect of celllulite on clothing (0=no effects at all; 10=very much affects) -Subjects were asked to rate their level of pain from 0 -10 (0 = no pain and 10 = worst possible pain) • Adverse events and expected treatment effects (effects more than moderate in severity were considered adverse events)
Single Site Analyses
• One of the registry sites conducted additional pilot analyses of efficacy including: -3D Vectra imaging of the treatment areas to quantitatively assess changes in dimple depth and volume -Blinded investigator assessment of 2D photography • A total of 13 patients at this site were included in the 3D image analyses and the blinded investigator assessment of 2D photography
Single Site Analysis: 3D Analysis of Dimple Depth and Volume
• 145 dimples treated with TS-GS in 13 subjects; 3D Vectra image analyses were conducted using standardized photos
• Mean improvement in volume was 67.4%
• Mean improvement in height of the dimple was 58.4%
REGISTRY DESIGN 3D ANALYSIS 3D ANALYSIS RESULTS

Single Site Analysis: Blinded Physician Assessment of Improvement
• At 180 days, the majority of patients, the majority of patients were rated >50% improved by blinded physicians (both dimple depth and overall improvement; REGISTRY RESULTS
• Information gathered within the registry aligns with the pivotal study conducted previously 2,3
• All patients experienced mild to moderate treatment effects, but no further treatment was required for any patient
• Quantitative image analysis directly supports the subject-and physician-assessed efficacy data by demonstrating objective improvements in dimple depth 
Adverse Events and Expected Treatment Side Effects
• All subjects experienced some mild treatment effects, but no further treatment was required for any subject.
• The majority of procedure-related adverse events resolved by 90 days • The most common effects were petechiae, bleeding and blanching, red spots from needle punctures, and fluid accumulation • Mild to moderate • Only 1 adverse event (induration) was reported • There were no serious adverse events reported 
CONCLUSIONS
